{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-208139","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.789267+00:00","generated_at":"2026-06-11T17:59:21.369150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102","bullets":["Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.","ENVISION Phase 3 trial met primary endpoint: 79.2% complete response at 3 months in LG-IR-NMIBC patients.","ATLAS Phase 3 showed 55% reduction in recurrence/progression/death risk for UGN-102+TURBT vs TURBT alone.","Completed $120M private placement of ordinary shares and pre-funded warrants to support UGN-102 launch.","Cash and equivalents $55.3M at June 30, 2023, excluding $120M proceeds; FY revenue guidance $76-86M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-208139","json":"https://secwatch.observer/filing/0001193125-23-208139.json","markdown":"https://secwatch.observer/filing/0001193125-23-208139.md","text":"https://secwatch.observer/filing/0001193125-23-208139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/0001193125-23-208139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/d509909d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:59:21.369150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c201e3a272c1ab28e1ce71d5309211d9983b64f","claim":"UroGen Pharma Ltd. reported the second quarter ended June 30, 2023 results: revenue $21.1 million.","evidence_excerpt":"UroGen reported net product revenue of JELMYTO for the second quarter 2023 of $21.1 million, compared to $16.6 million in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523208139/0001193125-23-208139-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$21.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}